Foreign Corrupt Practices Act
Publications
News
Fate Therapeutics Announces Completion of $173.1 Million Public Offering
View More
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
View More
FCPA Successor Liability (Harvard Law School Forum on Corporate Governance and Financial Regulation)
View More
DOJ Gives Mixed Messages On False Claims Act Enforcement (New York Law Journal)
View More
Contacts
A
- Administrative Law and FDA Litigation
- Agribusiness
- Antitrust + Competition
- Appellate and Supreme Court Litigation
- Artificial Intelligence + Machine Learning
B
C
- Cannabis
- Capital Markets
- China
- Class Actions
- CleanTech
- Complex Litigation + Dispute Resolution
- Consumer Financial Services
- Consumer Financial Services Enforcement + Government Investigations
- Consumer Financial Services Litigation
- Copyrights
- Corporate Social Responsibility Law + Policy
- Crowdfunding
D
- Debt Capital Markets
- Debt Finance
- Derivatives
- Digital Currency + Blockchain Technology
- Direct Listings
- Distressed Real Estate
E
F
- Fair + Responsible Lending
- False Claims Act
- FDA
- Financial Industry
- Financial Industry Advisory Services
- Financial Industry Litigation
- Financial Industry Litigation Services
- Financial Industry Transactional Services
- Financial Restructuring
- Fintech
- Food + Healthy Living
- Foreign Corrupt Practices Act
G
- Gaming + Gambling
- Global Trade
- Government Contracts + Disputes
- Government Investigations + Enforcement
- Growth Equity
H
- Hatch-Waxman, Biologics and Biosimilars Litigation
- Healthcare
- Healthcare Investigations
- Healthcare IT, Tech + Digital Health
- Healthcare Litigation
- Healthcare Regulatory
- Healthcare Services
- Hedge Funds
- Higher Education
- Hospitality + Leisure
I
- Impact + Responsible Investing
- India
- Insurance
- Intellectual Property
- Investment Management
- Investment Management Litigation
- Israel
- ITC 337 Proceedings
L
- Late Stage Drug Development
- Leasing
- Life Sciences
- Life Sciences Asia
- Life Sciences Collaborations + Licensing
- Life Sciences Emerging Companies
- Life Sciences Europe
- Life Sciences IPOs + Capital Markets
- Life Sciences M + A
- Life Sciences Patent Prosecution + Counseling
- Life Sciences Securities Litigation + Healthcare Fraud
M
N
O
P
- Patent Litigation
- Patent Prosecution + Counseling
- Patent Trial + Appeal Board
- Pharmaceuticals
- Privacy + Cybersecurity
- Private Equity
- Private Equity Asia
- Private Equity France
- Private Equity Germany
- Private Equity UK
- Private Equity US East Coast
- Private Equity US West Coast
- Private Investment Funds
- Products Litigation and Counseling
- Proposition 65 + Food Labeling Litigation
- Propsci
- Proptech
- Public Companies
R
- Real Estate Acquisitions + Dispositions
- Real Estate Design + Construction
- Real Estate Development + Permitting
- Real Estate Dispute Resolution
- Real Estate Finance + Restructurings
- Real Estate Industry
- Real Estate Investment Funds
- Real Estate Joint Ventures
- Real Estate Tax
- REITs and Real Estate M+A
- Risk Management + Insurance
S
- Search Funds
- Secondaries
- Securities + Shareholder Litigation
- Shareholder Activism
- Special Purpose Acquisition Companies (SPACs)
- Strategic Technology Transactions and Licensing
T
- Tax
- Tax-Exempt Organizations
- Technology
- Technology Europe
- Trade Secrets + Restrictive Covenants
- Trademarks
- Transportation
- Trusts + Estates Court Practice
- Trusts + Estates Planning
- Trusts + Estates Planning Advisory Services
U
V
W